Moderna Inc (MRNA)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 1,927,000 | 2,907,000 | 3,205,000 | 6,848,000 | 2,624,000 |
| Short-term investments | US$ in thousands | 5,098,000 | 5,697,000 | 6,697,000 | 3,879,000 | 1,984,000 |
| Total current liabilities | US$ in thousands | 2,206,000 | 3,015,000 | 4,923,000 | 9,128,000 | 4,389,000 |
| Cash ratio | 3.18 | 2.85 | 2.01 | 1.18 | 1.05 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,927,000K
+ $5,098,000K)
÷ $2,206,000K
= 3.18
The cash ratio of Moderna Inc has shown a consistent upward trend over the past five years, indicating the company's improving liquidity position. The ratio has increased from 1.05 in December 2020 to 3.18 in December 2024. This suggests that Moderna Inc has significantly more cash and cash equivalents compared to its current liabilities, providing a strong indication of the company's ability to meet its short-term financial obligations. The steady increase in the cash ratio reflects a healthy and robust financial position for Moderna Inc, which may provide the company with greater flexibility and security in managing its financial obligations and pursuing future growth opportunities.
Peer comparison
Dec 31, 2024